Isradipine
Isradipine structure
|
Common Name | Isradipine | ||
|---|---|---|---|---|
| CAS Number | 75695-93-1 | Molecular Weight | 371.387 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 501.9±60.0 °C at 760 mmHg | |
| Molecular Formula | C19H21N3O5 | Melting Point | 166-168°C | |
| MSDS | Chinese USA | Flash Point | 257.4±32.9 °C | |
|
Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
Brain 137(Pt 8) , 2287-302, (2014) Dopamine midbrain neurons within the substantia nigra are particularly prone to degeneration in Parkinson's disease. Their selective loss causes the major motor symptoms of Parkinson's disease, but the causes for the high vulnerability of SN DA neurons, compa... |
|
|
Analysis of responses to the TRPV4 agonist GSK1016790A in the pulmonary vascular bed of the intact-chest rat.
Am. J. Physiol. Heart Circ. Physiol. 306(1) , H33-40, (2014) The transient receptor potential vanilloid 4 (TRPV4) channel is a nonselective cation channel expressed on many cell types, including the vascular endothelium and smooth muscle cells. TRPV4 channels play a role in regulating vasomotor tone and capillary perme... |
|
|
L-type calcium channel blockade alleviates molecular and reversal spatial learning and memory alterations induced by entorhinal amyloid pathology in rats.
Behav. Brain Res. 237 , 190-9, (2013) The entorhinal cortex (EC) is one of the most vulnerable brain regions that is affected by beta amyloid (Aβ) in the early phases of Alzheimer's disease (AD). Calcium dyshomeostasis is one reason of Aβ pathology and the role of calcium channel blockers (CCBs) ... |
|
|
Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.
Clin. Pharm. 12(4) , 261-75, (1993) The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed. Felodipine and isradipine are new calcium-channel-blocking agents with FDA-approved labeling for use in the treatment of essen... |
|
|
Antiatherosclerotic actions of isradipine.
J. Cardiovasc. Pharmacol. 19 Suppl 3 , S29-31, (1992) Isradipine, a calcium antagonist of the dihydropyridine type, shows antiatherosclerotic actions that interfere with all three main mechanisms of atherosclerosis. These actions are mediated by the release of prostaglandin I2 and endothelium-derived relaxing fa... |
|
|
Experimental and clinical effects of isradipine relevant to atherosclerosis.
Am. J. Hypertens. 7(7 Pt 2) , 30S-34S, (1994) A number of studies in experimental animal models have demonstrated the potential direct antiatherosclerotic effects of calcium antagonists. This class of compounds can influence several processes that are involved in the development of atherosclerotic lesion... |
|
|
Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine.
J. Clin. Pharmacol. 34(12) , 1164-72, (1994) In the treatment of hypertension in renally impaired patients, normalization of blood pressure alone may not be sufficient to prevent significant morbidity to the kidneys. Treatment must reduce pressure in the renal vasculature, otherwise glomerular filtratio... |
|
|
Antihypertensive therapy with isradipine in patients with special safety concerns.
Angiology 45(12) , 997-1008, (1994) Treatment of hypertension in the complicated patient requires a specialized approach focusing on the treatment of the blood pressure and concurrent medical problems. Therapy must be chosen in consideration of the patient's age, multiple illnesses, declining o... |
|
|
Isradipine.
J. Clin. Pharm. Ther. 16(2) , 79-91, (1991) Isradipine is a potent dihydropyridine calcium channel blocker. It is highly selective for vascular smooth muscle, with very few negative inotropic or chronotropic effects. It may have minor depressant effects on the sinoatrial node, hence reducing the incide... |
|
|
Isradipine--another calcium-channel blocker for the treatment of hypertension and angina.
Ann. Pharmacother. 26(6) , 789-99, (1992) To review the pharmacology, pharmacokinetic disposition, dose recommendations, adverse effects, drug interactions, and efficacy of isradipine in patients with hypertension or ischemic heart disease.Data from scientific literature were extracted, evaluated, an... |